Navigation Links
Anthera Pharmaceuticals Promotes Colin Hislop, M.D., to Chief Medical Officer
Date:6/3/2010

ma‚ and infectious disease. While Vice President of Clinical Research at CV Therapeutics‚ Dr. Hislop was the development leader for the company's first product, Ranexa® (ranolazine), and championed the NDA efforts for this cardiovascular compound. Prior to CVT‚ Dr. Hislop spent seven years at Proctor and Gamble as the worldwide clinical development manager for P&G's osteoporosis drug, Actonel® (risedronate sodium). He also worked at Eli Lilly and Company in the UK as a medical advisor for the endocrinology group. Dr. Hislop has a B.Sc. from University of Surrey in Medical Biochemistry and an M.D., B.S. from the University of London.

Dr. Pennington has over 25 years of experience in the pharmaceutical industry during which he was responsible for 14 NDA and BLA approvals in the United States and 10 product approvals in countries outside the US. He joined Anthera in 2007 from CoTherix, Inc. where he served as Executive Vice President and Chief Medical Officer of a biopharmaceutical company focused on licensing, developing and commercializing therapeutic products for the treatment of cardiovascular diseases. Previously, he was Executive Vice President, Medical and Scientific Affairs and Chief Medical Officer of InterMune, Inc., a publicly-traded biopharmaceutical company focused on the development, applied research and marketing of life-saving therapies for pulmonary and hepatic diseases, and also served as Vice President of Biological and Biotechnology Clinical Development of Bayer Corporation for 11 years. Prior to entering the pharmaceutical industry, Dr. Pennington also has years of experience in academia at Harvard Medical School and the University of California, San Francisco. He attended the University of Oregon School o
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial
2. Antheras Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease
3. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
4. Anthera Presents Data on Varespladib at ATVB Meeting
5. Anthera Pharmaceuticals Forms Scientific Advisory Board
6. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
7. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
8. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
9. Amylin Pharmaceuticals to Present at the 2010 Jefferies Global Life Sciences Conference
10. Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
11. Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... when the transplant recipient,s immune system identifies the transplanted ... previously thought that T cells, the immune cells that ... as chemokines in order to migrate to the transplanted ... Clinical Investigation , Fadi Lakkis and colleagues at the ... stimulation of T cells is not required for migration. ...
(Date:5/17/2013)... 2013 - Elsevier, a world-leading provider of scientific, technical ... publication of a recent study in Reproductive ... showing that those with an abnormal chromosomal composition can ... developed to blastocysts, thereby classifying the risk of genetic ... same group has undertaken a retrospective study, using their ...
(Date:5/17/2013)... May 17, 2013 •    First of its ... for sustainability ,     New facility will help solve ... , Syngenta unveiled its new crop research ... company’s RTP Innovation Center. The first of its kind, ... simulate any agricultural climate and precisely measure plant inputs ...
(Date:5/17/2013)... 17, 2013  Cellular Biomedicine Group (OTCQB: CBMG) ... of the total projected enrollment required for its ... preliminary efficacy of the medical technology haMPC (Human ... (KOA). To date the trial has had no ... Phase I open label clinical research trial for ...
Breaking Biology Technology:Breakthrough for IVF? 2Breakthrough for IVF? 3Syngenta Opens Unique $72 Million Advanced Crop Lab 2Syngenta Opens Unique $72 Million Advanced Crop Lab 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2
... NEEDHAM, Mass., Feb. 24 Environment of Care ... tips to better achieve and maintain their organization,s ... of a new series of brief, web-based audio interviews ... free to play or download at http://www.eheinc.com/ec_bits.htm ...
... /PRNewswire-Asia-FirstCall/ -- China Sky One,Medical, Inc. ("China ... CSKI ), a,leading fully integrated ... Republic of China ("PRC"), today announced that ... Pharmaceutical Company ("Jin,Chuang"), signed an exclusive distribution ...
... 24 Eiger BioPharmaceuticals, Inc.,a start-up biotechnology company ... million in a Series A financing co-led by ... instrumental in the formation,of the company and recruitment ... board of,directors by general partners Nina Kjellson and ...
Cached Biology Technology:Web-based Audio Interviews Keep Environment of Care Managers Up-to-Date on Key EC Compliance Issues 2China Sky One Medical, Inc. Signs Exclusive Distribution Agreement with Shaanxi Buchang Group for Naftopidil Dispersible Tablets 2China Sky One Medical, Inc. Signs Exclusive Distribution Agreement with Shaanxi Buchang Group for Naftopidil Dispersible Tablets 3Eiger BioPharmaceuticals Raises $7.1 Million 'A' Round 2
(Date:5/16/2013)... the bone marrow in the liver, the spleen ... show that a specific type of immune cell facilitates ... hematopoiesis is essential for the function of the immune ... the liver and the spleen. Later the process is ... serves as the sole source of blood cells for ...
(Date:5/16/2013)... Ekwoge Enang Abwe, a conservationist working in Cameroon and ... program, has just been awarded the prestigious Whitley award. ... is often called "The Green Oscars" because it celebrates ... conservationists working in developing countries. Abwe was selected ... about and preserve Cameroon,s Ebo Forest and its wildlife ...
(Date:5/16/2013)... , May 16, 2013 ... Enhancement Award on Tuesday to Germany,s ... exceptional biometric border control system. DERMALOG has ... the Best Practices Award in the category Global Biometrics ... cutting edge Biometric   Border Control System . ...
Breaking Biology News(10 mins):Herpes infections: Natural killer cells activate hematopoiesis 2Cameroon researcher wins prestigious 'Green Oscar' 2Cameroon researcher wins prestigious 'Green Oscar' 3Global Biometrics and Border Control Award for DERMALOG 2Global Biometrics and Border Control Award for DERMALOG 3Global Biometrics and Border Control Award for DERMALOG 4
... within cells and increase a person,s susceptibility to bacterial ... new study published in Disease Models & Mechanisms ... bacteria Legionella , is facilitated by an increased ... mitochondrial disease. , Patients with mitochondrial disease exhibit a ...
... Brook, N.Y., July 27, 2009 - Temperature explains ... crustaceans, and lizards live longer at higher latitudes than ... in the Proceedings of the National Academy of ... Stephan Munch and Ph.D. candidate Santiago Salinas, both of ...
... Angeles, London, New Delhi, Singapore and Washington DC (July ... issue of Medical Decision Making , a large-scale, ... hospital resources even with an extremely effective public health ... attack and initiating a response to it. The ...
Cached Biology News:Stress signals link pre-existing sickness with susceptibility to bacterial infection 2Warmer environment means shorter lives for cold-blooded animals 2Bioterrorism and disaster preparedness explored in special issue of Medical Decision Making 2
... Simultaneously perform 96 assays on one plate. ... microarray plate with 96 (7mm x 7mm) ... gene expression, or screening analysis studies. Unlike ... fit gasket, eliminating the presence of contaminating ...
Bio-Plex Manager software, version 3.0, 5 license netshare, is a five-user software package that provides access to data from the Bio-Plex suspension array system from a server. This version does not...
... vapor-tight adhesive chambers for sealing hybridization reactions on ... a sample on a glass slide. Reaction solution ... the ports are then sealed with plastic sealing ... allow exchange of reaction fluid. These chambers enclose ...
... of integrins in vascular proliferation, adhesion, and ... family of cell adhesion receptors consists of ... an a and b subunit that associate ... functional diversity of the integrin family are ...
Biology Products: